ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

ADMA Biologics, Inc.NASDAQ: ADMA

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit grows, but more slowly than its trailing trend

Q2 FY2026 gross profit of $86.28M rose 28.3% year over year, behind the +31.9% change in trailing-twelve-month gross profit. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at +102.5% a year.

Context

  • Gross profit amounted to 57.4% of revenue in FY2025, up 5.9 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +28.3% toward the trailing-twelve-month pace of +31.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$86.28M+6.8% QoQ
Last fiscal yearDec 2025
$292.77M+33.3% YoY
LTMJun 2026
$331.47M+31.9% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.3%——
1 year+33.3%——
3-year CAGR+102.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
292.77M USD
Year-over-year change
+33.3%
4-year CAGR
+297.5%

Gross Profit vs competitors

How ADMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.9% is the 3rd highest of 4, against a peer median of +50.2%.
  • Gross profit amounts to 64.7% of revenue for ADMA, versus a peer median of 92.0%.
ADMA Competitors
Gross Profit for ADMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRFSGrifols, S.A.LTM Jun 2026€2.77B EUR-6.0%+5.2%37.2%
ADMAADMA Biologics, Inc.LTM Jun 2026$331.47M USD+31.9%+102.5%64.7%
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.41M USD+1784.1%-29.4%100.0%
IVVDInvivyd, Inc.LTM Mar 2026$51.41M USD+50.2%—92.0%
Peer median (excluding ADMA) —+50.2%-12.1%92.0%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.